Literature DB >> 23881437

Translation, cross-cultural adaptation, and validation of the Mouth Handicap in Systemic Sclerosis questionnaire (MHISS) into the Dutch language.

A A Schouffoer1, E Strijbos, A J M Schuerwegh, L Mouthon, T P M Vliet Vlieland.   

Abstract

The Mouth Handicap in Systemic Sclerosis (MHISS) is a French-generic questionnaire evaluating mouth-opening restriction, dryness, and esthetic concerns. The aim of this study was to translate and adapt the MHISS questionnaire into the Dutch language and evaluate its psychometric properties. The MHISS was translated according to international guidelines, field-tested among 16 systemic sclerosis (SSc) patients, and adapted. Subsequently, the Dutch MHISS was administered to 52 SSc patients visiting the outpatient or day patient clinic of a university hospital and readministered after 2 weeks. Internal consistency was tested by computing Cronbach's alpha. Test-retest reliability was determined by computing the intraclass correlation coefficient (ICC) and validity by determining associations with measures of overall functioning (Health Assessment Questionnaire (HAQ)), maximum mouth opening (MMO, in millimeter), subjective xerostomia (visual analog scale), and objective xerostomia (Saxon test). Patients had mean ± standard deviation (SD) age and disease duration of 55 ± 21 and 7.2 ± 7.3 years. Twenty-seven (52 %) patients had diffuse cutaneous SSc. The mean Dutch MHISS score was 17.5 (SD 10.0) with Cronbach's alpha being 0.862. Dutch MHISS scores differed significantly between patients with high and low disability levels (HAQ, MMO, and subjective and objective xerostomia divided according to the median; paired t test). Spearman rank correlations with HAQ (r = 0.599, p = 0.000), MMO (r = -0.518, p = 0.000), and subjective xerostomia (r = 0.536, p = 0.000) were moderate; correlation with objective xerostomia did not reach statistical significance. The ICC was 0.94. The Dutch version of the MHISS demonstrated good psychometric properties and is useful in assessing mouth disability in SSc patients.

Entities:  

Mesh:

Year:  2013        PMID: 23881437     DOI: 10.1007/s10067-013-2321-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  22 in total

1.  Classification criteria for Sjögren's syndrome.

Authors:  C Vitali
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

2.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  Quality criteria were proposed for measurement properties of health status questionnaires.

Authors:  Caroline B Terwee; Sandra D M Bot; Michael R de Boer; Daniëlle A W M van der Windt; Dirk L Knol; Joost Dekker; Lex M Bouter; Henrica C W de Vet
Journal:  J Clin Epidemiol       Date:  2006-08-24       Impact factor: 6.437

Review 4.  Periodontal manifestations in systemic sclerosis: a review.

Authors:  Anshul Mehra; Suneet Kumar
Journal:  Dent Today       Date:  2008-06

5.  Generalized scleroderma; hidebound disease, its relation to the oral cavity, with case history and dental restoration.

Authors:  I H ROSENTHAL
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1948-11

Review 6.  Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines.

Authors:  F Guillemin; C Bombardier; D Beaton
Journal:  J Clin Epidemiol       Date:  1993-12       Impact factor: 6.437

7.  Effects of a nonsurgical exercise program on the decreased mouth opening in patients with systemic scleroderma.

Authors:  G Pizzo; G A Scardina; P Messina
Journal:  Clin Oral Investig       Date:  2003-07-09       Impact factor: 3.573

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

Review 9.  Small mouths ... Big problems? A review of scleroderma and its oral health implications.

Authors:  Jonathan B Albilia; David K Lam; Nick Blanas; Cameron M L Clokie; George K B Sándor
Journal:  J Can Dent Assoc       Date:  2007-11       Impact factor: 1.316

10.  Efficacy of a tailored rehabilitation program for systemic sclerosis.

Authors:  S Maddali Bongi; A Del Rosso; F Galluccio; G Tai; F Sigismondi; M Passalacqua; G Landi; M Baccini; M L Conforti; I Miniati; M Matucci-Cerinic
Journal:  Clin Exp Rheumatol       Date:  2009 May-Jun       Impact factor: 4.473

View more
  4 in total

1.  Oral disease profiles in chronic graft versus host disease.

Authors:  C W Bassim; H Fassil; J W Mays; D Edwards; K Baird; S M Steinberg; E W Cowen; H Naik; M Datiles; P Stratton; R E Gress; S Z Pavletic
Journal:  J Dent Res       Date:  2015-03-04       Impact factor: 6.116

2.  New risk model is able to identify patients with a low risk of progression in systemic sclerosis.

Authors:  Nina Marijn van Leeuwen; Marc Maurits; Sophie Liem; Jacopo Ciaffi; Nina Ajmone Marsan; Maarten Ninaber; Cornelia Allaart; Henrike Gillet van Dongen; Robbert Goekoop; Tom Huizinga; Rachel Knevel; Jeska De Vries-Bouwstra
Journal:  RMD Open       Date:  2021-05

3.  Clinical, functional and health-related quality of life correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis: a cross-sectional survey.

Authors:  Christelle Nguyen; Brigitte Ranque; Thierry Baubet; Alice Bérezné; Caroline Mestre-Stanislas; François Rannou; Agathe Papelard; Sandrine Morell-Dubois; Michel Revel; Marie-Rose Moro; Loïc Guillevin; Serge Poiraudeau; Luc Mouthon
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

4.  Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis.

Authors:  Maaike Boonstra; Jaap A Bakker; Annette Grummels; Maarten K Ninaber; Nina Ajmone Marsan; Corrie M Wortel; Tom W J Huizinga; Suzana Jordan; Anna-Maria Hoffman-Vold; Oliver Distler; René E M Toes; Hans Ulrich Scherer; Jeska K de Vries-Bouwstra
Journal:  Arthritis Rheumatol       Date:  2020-09-29       Impact factor: 10.995

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.